Dan Marshak is no stranger to overseeing technology operations for a life sciences company, but it’s new for PerkinElmer to have somebody doing that task on such a high level. Marshak, who recently became PerkinElmer’s CSO — a newly created position — says the post was designed “to bring someone into the highest level of management to work with the CEO and board members” to help ensure consistency in scientific and business strategy for the whole company.
Part of that strategy will be concentrated on the field’s, and the company’s, evolution into diagnostics, Marshak says. He will oversee technology and science, including “not only instrumentation but also reagents for genomics and proteomics and moving toward diagnostics,” he says. “As we enter the new generation of personalized medicine and regenerative medicine and new technologies in both medical care and diagnostics, drug development has a lot of needs right now.” For example, he points to detectors such as lighting systems and photonics, which have made their mark in the telecom and aerospace industries, as potential sources of new innovation.
Marshak will also be responsible for keeping an eye on up-and-coming technology available through licensing and acquisitions.
Prior to PerkinElmer, Marshak was vice president and CTO for the bioscience business at Cambrex, a company that focused on research reagents as well as cell therapy. He also worked at Osiris Therapeutics in Baltimore, and was a senior investigator for several years at Cold Spring Harbor Laboratory. His research there centered on signal transduction in neuroscience and in cancer.
— Meredith Salisbury